Biosimilars Market Overview:
Global biosimilars/follow-on-biologics market was valued at $1,358 million in 2013, and is expected to reach $35,032 million by 2020, supported by a CAGR of 60.8% during the forecast period 2014 to 2020. Biosimilars or follow-on-biologics are the copied version of reference biologics, which are protected by intellectual rights that will expire soon.
Patent expiration is the major driving factor of the market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Biosimilar medicines have witnessed growth over the past five and six years.
Regulations for this biologic medical product plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the global biosimilars market. Regulations in the European union are considered benchmark around the global, as the guidelines proposed are most stringent for validation and commercialization of biosimilars. High profitability is the attractive aspect that is enticing companies to invest in the biosimilars industry.
Geographically, Biosimilars market is segmented into North America, Europe, Asia-Pacific and LAMEA. Due to favorable regulatory policies designed by the European Medical Association, the European market has been maximizing on the market. Asia-Pacific and LAMEA market would witness a substantial rise in the use of biosimilars, as the demand for cost effective treatment is growing due to the prevalence of chronic diseases. Collaboration with local players would be a key opportunity that could be fully explored by the biosimilars manufacturers in developing economies. Many companies such as Amgen and Novartis are collaborating with Asian players to gain a foothold in the biopharmaceutical market.
Europe was the first region to draft guidelines for approval of biosimilars in 2006. Nevertheless, in 2008, the first biosimilars version of Granulocyte colony-stimulating factor (G-CSF) was introduced in the European Union under the regulatory guidance of European Medical Association (EMA). Currently, there are three biosimilar versions of G-CSF available in the European market, namely Ratiograstim/Tevagrastim/Biograstim, Zarzio/Filgrastim Hexal and Nivestim/Pliva/Mayne filgrastim. Adding to the G-CSF biosimilars, the insulin biosimilars also showcase tremendous potential in the future.
BIOSIMILARS MARKET KEY BENEFITS
- The report on Biosimilars market 2020 is segmented in a strategic division to gain deeper insights into the market dynamics, size and understand the competitive environment of the overall market
- Financial market forecast is provided for the next eight years by considering 2013 as the base year
- Comprehensive and quantitative data analysis about changing trends, intensifying competition and opportunities in biosimilars market 2020 are provided to make better business decisions
- Porters Five Forces model and SWOT analysis of the overall Biosimilars industry is provided to help stakeholders gain strategic insights of the market
- Deep dive analysis of key players and strategies adopted by them are expounded to provide valuable information on the top contenders in the market
- Identification of key investment pockets for the market is strategically dealt to assist the stakeholders
BIOSIMILARS MARKET KEY DELIVRABLES
Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography.
- Monoclonal Antibodies (MAb) Technology
- Recombinant DNA Technology (rDNA technology)
- Nuclear magnetic resonance (NMR) technology
- Mass Spectrometry
- Western Blotting
- Recombinant Non-Glycosylated Protein
- Human Growth Hormone
- Granulocyte colony stimulating factor (G-CSF)
- Recombinant Glycosylated Protein
- Monoclonal antibodies
- LH-RH (Leuprolide)
- Blood disorders
- Chemotherapy induce Anaemia
- Pulmonary embolism
- Oncology diseases
- Lungs cancer
- Colorectal cancer
- Breast cancer
- Cervical cancer
- Prostate cancer
- Chronic and autoimmune diseases
- Multiple sclerosis
- Cystic Fibrosis
- Rheumatoid arthritis (RA)
- Growth hormone deficiencies
- Contract Research and Manufacturing Services (CRAMS)
- Clinical Trials
- North America